Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory

International Journal of Cancer

Volumn 136, Issue 3, 2015, Pages 503-515

  Dionne, Kalen R ^a,b,c   Warnakulasuriya, Saman ^d   Zain, Rosnah Binti ^a   Cheong, Sok Ching ^a,b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^c UNIVERSITY OF COLORADO   (United States)

^d King's and St Thomas' School of Medicine and Dentistry   (United Kingdom)

Author keywords

Biomarker; Cancer; Erythroplakia; Leukoplakia; Oral; Oral cancer; Oral submucous fibrosis; Premalignant; Review; Squamous cell carcinoma

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; ACETYLSALICYLIC ACID; AMINOLEVULINIC ACID; BENZO[A]PYRENE; BETA CAROTENE; BLACK RASPBERRY GEL; BOWMAN BIRK INHIBITOR; CELECOXIB; CURCUMIN; CYCLIN D1; DIBENZO[A,L]PYRENE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GREEN TEA EXTRACT; KETOROLAC; MOLECULAR MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PLACEBO; PLANT MEDICINAL PRODUCT; PODOPLANIN; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; RAPAMYCIN; RETINOIC ACID; RETINOL; SULINDAC; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN;

ANEUPLOIDY; CANCER EPIDEMIOLOGY; CANCER INHIBITION; CANCER MORPHOLOGY; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL RESEARCH; DNA CONTENT; DNA STRAND BREAKAGE; DYSPLASIA; EARLY DIAGNOSIS; ERYTHROPLASIA; FOLLOW UP; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; LEUKOPLAKIA; MALIGNANT TRANSFORMATION; MOUTH CANCER; MOUTH CARCINOMA; MOUTH LESION; MOUTH SQUAMOUS CELL CARCINOMA; NOMENCLATURE; NONHUMAN; ORAL BIOPSY; ORAL SURGERY; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; AGED; CARCINOMA, SQUAMOUS CELL; GENETICS; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PLOIDY;

AGED; CARCINOMA, SQUAMOUS CELL; CYCLIN D1; DNA; HUMANS; LEUKOPLAKIA, ORAL; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; PLOIDIES;

EID: 84911005981     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28754     Document Type: Review

References (164)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55: 74-108.
2. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
3. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
4. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004;101:3-27.
5. Mork J. Forty years of monitoring head and neck cancer in Norway-no good news. Anticancer Res 1998;18:3705-8.
6. Haddad RI, Shin DM. Recent advances in head and neck cancer. New Engl J Med 2008;359:1143-54.
7. Das BR, Nagpal JK. Understanding the biology of oral cancer. Med Sci Monit 2002;8:RA258-67.
8. Warnakulasuriya S, Cain N. Screening for oral cancer: contributing to the debate. J Investig Clin Dent 2011;2:2-9.
9. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 2008;37:1-10.
10. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007;36:575-80.
11. Bhargava K, Smith LW, Mani NJ, et al. A follow up study of oral cancer and precancerous lesions in 57,518 industrial workers of Gujarat, India. Indian J Cancer 1975;12:124-9.
12. Mehta FS, Shroff BC, Gupta PC, et al. Oral leukoplakia in relation to tobacco habits. A tenyear follow-up study of Bombay policemen. Oral Surg Oral Med Oral Pathol 1972;34:426-33.
13. Nagao T, Ikeda N, Fukano H, et al. Incidence rates for oral leukoplakia and lichen planus in a Japanese population. J Oral Pathol Med 2005;34: 532-9.
14. Amarasinghe HK, Usgodaarachchi US, Johnson NW, et al. Betel-quid chewing with or without tobacco is a major risk factor for oral potentially malignant disorders in Sri Lanka: a case-control study. Oral Oncol 2010;46:297-301.
15. Bouquot JE. Oral leukoplakia and erythroplakia: a review and update. Pract Periodontics Aesthet Dent 1994;6:9-17; quiz 9.
16. Kleinman DV, Swango PA, Pindborg JJ, et al. Toward assessing trends in oral mucosal lesions: lessons learned from oral cancer. Adv Dent Res 1993;7:32-41.
17. Mehta FS, Pindborg JJ, Gupta PC, et al. Epidemiologic and histologic study of oral cancer and leukoplakia among 50,915 villagers in India. Cancer 1969;24:832-49.
18. Smith LW, Bhargava K, Mani NJ, et al. Oral cancer and precancerous lesions in 57,518 industrial workers of Gujarat, India. Indian J Cancer 1975;12:118-23.
19. Petti S. Pooled estimate of world leukoplakia prevalence: a systematic review. Oral Oncol 2003;39:770-80.
20. Malaysia DDMoH, ed. Dental epidemiological survey of adults in Peninsular Malaysia, 1974/75 edn. Malaysia: Dental Division Ministry of Health Malaysia, 1978. 98-9.
21. Mehta FS, Pindborg JJ, Hamner JE, III. Report on oral cancer and precancerous conditions in Indian rural populations, 1966-1969. Bombay: Basic Dental Research Unit, Tata Institute of Fundamental Research, 1971.
22. Zain RB, Ikeda N, Razak IA, et al. A national epidemiological survey of oral mucosal lesions in Malaysia. Commun Dent Oral Epidemiol 1997;25:377-83.
23. Ministry of Health. National oral health survey, Sri Lanka (2002/2003). Colombo: Ministry of Health, 2009.
24. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
25. Tanaka T, Ishigamori R. Understanding carcinogenesis for fighting oral cancer. J Oncol 2011; 2011:603740.
26. Lee CH, Ko AM, Warnakulasuriya S, et al. Intercountry prevalences and practices of betelquid use in south, southeast and eastern Asia regions and associated oral preneoplastic disorders: an international collaborative study by Asian betel-quid consortium of south and east Asia. Int J Cancer 2011;129:1741-51.
27. Moore MA, Ariyaratne Y, Badar F, et al. Cancer epidemiology in South Asia-past, present and future. Asian Pac J Cancer Prev 2010;11(Suppl 2):49-66.
28. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004;31:744-54.
29. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003;95: 1772-83.
30. Awan K, Yang Y, Morgan P, et al. Utility of toluidine blue as a diagnostic adjunct in the detection of potentially malignant disorders of the oral cavity-a clinical and histological assessment. Oral Dis 2012;18:728-33.
31. Awan KH, Morgan PR, Warnakulasuriya S. Evaluation of an autofluorescence based imaging system (VELscope) in the detection of oral potentially malignant disorders and benign keratoses. Oral Oncol 2011;47:274-7.
32. Awan KH, Morgan PR, Warnakulasuriya S. Utility of chemiluminescence (ViziLite) in the detection of oral potentially malignant disorders and benign keratoses. J Oral Pathol Med 2011; 40:541-4.
33. Scheer M, Neugebauer J, Derman A, et al. Autofluorescence imaging of potentially malignant mucosa lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;111:568-77.
34. Lee CK, Chi TT, Wu CT, et al. Diagnosis of oral precancer with optical coherence tomography. Biomed Opt Express 2012;3: 1632-46.
35. Yang SW, Lee YS, Chang LC, et al. Diagnostic significance of narrow-band imaging for detecting high-grade dysplasia, carcinoma in situ, and carcinoma in oral leukoplakia. Laryngoscope 2012;122:2754-61.
36. Petruzzi M, Lucchese A, Baldoni E, et al. Use of Lugol's iodine in oral cancer diagnosis: an overview. Oral Oncol 2010;46:811-13.
37. Maeda K, Suzuki T, Ooyama Y, et al. Colorimetric analysis of unstained lesions surrounding oral squamous cell carcinomas and oral potentially malignant disorders using iodine. Int J Oral Maxillofac Surg 2010;39:486-92.
38. Ohta K, Ogawa I, Ono S, et al. Histopathological evaluation including cytokeratin 13 and Ki-67 in the border between Lugol-stained and-unstained areas. Oncol Rep 2010;24:9-14.
39. Barnes L, Eveson J, Reichart PA, et al. World Health Organization classification of tumours-pathology & genetics. Head and neck tumours. Lyon: IARC Press, 2005.
40. Warnakulasuriya S, Reibel J, Bouquot J, et al. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008;37: 127-33.
41. Speight PM. Update on oral epithelial dysplasia and progression to cancer. Head Neck Pathol 2007;1:61-6.
42. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003;14:47-62.
43. Shafer WG, Waldron CA. Erythroplakia of the oral cavity. Cancer 1975;36:1021-8.
44. Mehanna HM, Rattay T, Smith J, et al. Treatment and follow-up of oral dysplasia-a systematic review and meta-analysis. Head Neck 2009; 31:1600-9.
45. Warnakulasuriya S, Kovacevic T, Madden P, et al. Factors predicting malignant transformation in oral potentially malignant disorders among patients accrued over a 10-year period in South East England. J Oral Pathol Med 2011;40: 677-683.
46. Schepman KP, van der Meij EH, Smeele LE, et al. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 1998;34:270-5.
47. Holmstrup P, Vedtofte P, Reibel J, et al. Longterm treatment outcome of oral premalignant lesions. Oral Oncol 2006;42:461-74.
48. Holmstrup P, Vedtofte P, Reibel J, et al. Oral premalignant lesions: is a biopsy reliable? J Oral Pathol Med 2007;36:262-6.
49. Saintigny P, Zhang L, Fan YH, et al. Gene expression profiling predicts the development of oral cancer. Cancer Prev Res (Phila) 2011;4:218-29.
50. Bosman FT. Dysplasia classification: pathology in disgrace? J Pathol 2001;194:143-4.
51. Silverman S, Bhargava K, Smith LW, et al. Malignant transformation and natural history of oral leukoplakia in 57,518 industrial workers of Gujarat, India. Cancer 1976;38:1790-5.
52. Abbey LM, Kaugars GE, Gunsolley JC, et al. Intraexaminer and interexaminer reliability in the diagnosis of oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:188-91.
53. Fleskens S, Slootweg P. Grading systems in head and neck dysplasia: their prognostic value, weaknesses and utility. Head Neck Oncol 2009;1:11.
54. Karabulut A, Reibel J, Therkildsen MH, et al. Observer variability in the histologic assessment of oral premalignant lesions. J Oral Pathol Med 1995;24:198-200.
55. Kujan O, Khattab A, Oliver RJ, et al. Why oral histopathology suffers inter-observer variability on grading oral epithelial dysplasia: an attempt to understand the sources of variation. Oral Oncol 2007;43:224-31.
56. Pindborg JJ, Reibel J, Holmstrup P. Subjectivity in evaluating oral epithelial dysplasia, carcinoma in situ and initial carcinoma. J Oral Pathol 1985;14:698-708.
57. Kujan O, Oliver RJ, Khattab A, et al. Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol 2006;42:987-93.
58. Fabarius A, Hehlmann R, Duesberg PH. Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet 2003;143:59-72.
59. Souto GR, Caliari MV, Lins CE, et al. Tobacco use increase the number of aneuploid nuclei in the clinically healthy oral epithelium. J Oral Pathol Med 2010;39:605-10.
60. Bremmer JF, Brakenhoff RH, Broeckaert MA, et al. Prognostic value of DNA ploidy status in patients with oral leukoplakia. Oral Oncol 2011; 47:956-60.
61. Femiano F, Scully C. DNA cytometry of oral leukoplakia and oral lichen planus. Med Oral Patol Oral Cir Bucal 2005;10(Suppl 1):E9-E14.
62. Hogmo A, Lindskog S, Lindholm J, et al. Preneoplastic oral lesions: the clinical value of image cytometry DNA analysis, p53 and p21/ WAF1 expression. Anticancer Res 1998;18:3645-50.
63. Klanrit P, Sperandio M, Brown AL, et al. DNA ploidy in proliferative verrucous leukoplakia. Oral Oncol 2007;43:310-6.
64. Mattila R, Alanen K, Syrjanen S. DNA content as a prognostic marker of oral lichen planus with a risk of cancer development. Anal Quant Cytol Histol 2004;26:278-84.
65. Bradley G, Odell EW, Raphael S, et al. Abnormal DNA content in oral epithelial dysplasia is associated with increased risk of progression to carcinoma. Br J Cancer 2010;103:1432-42.
66. Torres-Rendon A, Stewart R, Craig GT, et al. DNA ploidy analysis by image cytometry helps to identify oral epithelial dysplasias with a high risk of malignant progression. Oral Oncol 2009; 45:468-73.
67. Sperandio M, Brown AL, Lock C, et al. Predictive value of dysplasia grading and DNA ploidy for malignant transformation of oral potentially malignant disorders. Cancer Prev Res (Phila) 2013.
68. Bhattacharya A, Roy R, Snijders AM, et al. Two distinct routes to oral cancer differing in genome instability and risk for cervical node metastasis. Clin Cancer Res 2011;17:7024-34.
69. Kasamatsu A, Uzawa K, Usukura K, et al. Loss of heterozygosity in oral cancer. Oral Sci Int 2011;8:37-43.
70. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6:1702-10.
71. Partridge M, Pateromichelakis S, Phillips E, et al. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res 2000;60: 3893-8.
72. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996; 2:682-5.
73. Roz L, Wu CL, Porter S, et al. Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Res 1996;56:1228-31.
74. Papadimitrakopoulou VA, Izzo J, Mao L, et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res 2001;7: 3127-34.
75. Miracca EC, Kowalski LP, Nagai MA. High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer 1999;81:677-83.
76. Emilion G, Langdon JD, Speight P, et al. Frequent gene deletions in potentially malignant oral lesions. Br J Cancer 1996;73:809-13.
77. Partridge M, Emilion G, Falworth M, et al. Patient-specific mutation databases for oral cancer. Int J Cancer 1999;84:284-92.
78. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92.
79. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6: 357-62.
80. Zhang L, Poh CF, Williams M, et al. Loss of heterozygosity (LOH) profiles-validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) 2012;5:1081-9.
81. Warnakulasuriya S. p53 and oral precancer-a review. In: Varma AK, ed. Oral oncology, vol. 6. New Delhi: McMillan, 1998.
82. Abbas NF, Labib El-Sharkawy S, Abbas EA, et al. Immunohistochemical study of p53 and angiogenesis in benign and preneoplastic oral lesions and oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:385-90.
83. Kumar P, Kane S, Rathod GP. Coexpression of p53 and Ki 67 and lack of c-erbB2 expression in oral leukoplakias in India. Braz Oral Res 2012; 26:228-34.
84. Murti PR, Warnakulasuriya KA, Johnson NW, et al. p53 expression in oral precancer as a marker for malignant potential. J Oral Pathol Med 1998;27:191-6.
85. Shah NG, Trivedi TI, Tankshali RA, et al. Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. Int J Biol Markers 2007;22:132-43.
86. Soni S, Kaur J, Kumar A, et al. Alterations of rb pathway components are frequent events in patients with oral epithelial dysplasia and predict clinical outcome in patients with squamous cell carcinoma. Oncology 2005;68:314-25.
87. Nasser W, Flechtenmacher C, Holzinger D, et al. Aberrant expression of p53, p16INK4a and Ki-67 as basic biomarker for malignant progression of oral leukoplakias. J Oral Pathol Med 2011;40:629-35.
88. Kotelnikov VM, Coon JSt, Mundle S, et al. Cyclin D1 expression in squamous cell carcinomas of the head and neck and in oral mucosa in relation to proliferation and apoptosis. Clin Cancer Res 1997;3:95-101.
89. Rousseau A, Lim MS, Lin Z, et al. Frequent cyclin D1 gene amplification and protein overexpression in oral epithelial dysplasias. Oral Oncol 2001;37:268-75.
90. Raju B, Mehrotra R, Oijordsbakken G, et al. Expression of p53, cyclin D1 and Ki-67 in premalignant and malignant oral lesions: association with clinicopathological parameters. Anticancer Res 2005;25:4699-706.
91. Kovesi G, Szende B. Prognostic value of cyclin D1, p27, and p63 in oral leukoplakia. J Oral Pathol Med 2006;35:274-7.
92. Turatti E, da Costa Neves A, de Magalhaes MH, et al. Assessment of c-Jun, c-Fos and cyclin D1 in premalignant and malignant oral lesions. J Oral Sci 2005;47:71-6.
93. Liu SC, Hu Y, Sauter ER, et al. Image analysis of p53 and cyclin D1 expression in premalignant lesions of the oral mucosa. Anal Quant Cytol Histol 1999;21:166-73.
94. Liu SC, Sauter ER, Clapper ML, et al. Markers of cell proliferation in normal epithelia and dysplastic leukoplakias of the oral cavity. Cancer Epidemiol Biomarkers Prev 1998;7:597-603.
95. Oliver RJ, MacDonald DG. G1 cyclins in oral epithelial dysplasia. J Oral Pathol Med 2001;30: 80-6.
96. Poh CF, Zhu Y, Chen E, et al. Unique FISH patterns associated with cancer progression of oral dysplasia. J Dent Res 2012;91:52-7.
97. Mishra R, Das BR. Cyclin D1 expression and its possible regulation in chewing tobacco mediated oral squamous cell carcinoma progression. Arch Oral Biol 2009;54:917-23.
98. Shintani S, Mihara M, Nakahara Y, et al. Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol 2002;38:235-43.
99. Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol 2012;3:283.
100. Inoue H, Miyazaki Y, Kikuchi K, et al. Podoplanin expression during dysplasia-carcinoma sequence in the oral cavity. Tumour Biol 2012; 33:183-94.
101. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008;26: 354-60.
102. Feng JQ, Mi JG, Wu L, et al. Expression of podoplanin and ABCG2 in oral erythroplakia correlate with oral cancer development. Oral Oncol 2012;48:848-52.
103. Kreppel M, Kreppel B, Drebber U, et al. Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications. Oral Dis 2012;18:692-9.
104. Gopal Ray J. Pathogenesis and malignant transformation of oral submucous fibrosis: Possible role of lysly oxidase (lox) and NADPH quinone oxidoreductase 1 (NQO1) gene polymorphis. PhD Thesis. India: Yenepoya University, 2013.
105. Tilakaratne WM, Iqbal Z, Teh MT, et al. Upregulation of HIF-1alpha in malignant transformation of oral submucous fibrosis. J Oral Pathol Med 2008;37:372-7.
106. Chaw SY, Majeed AA, Dalley AJ, et al. Epithelial to mesenchymal transition (EMT) biomarkers-E-cadherin, beta-catenin, APC and Vimentin-in oral squamous cell carcinogenesis and transformation. Oral Oncol 2012;48:997-1006.
107. Das RK, Pal M, Barui A, et al. Assessment of malignant potential of oral submucous fibrosis through evaluation of p63, E-cadherin and CD105 expression. J Clin Pathol 2010;63:894-9.
108. Lindsay J, McDade SS, Pickard A, et al. Role of DeltaNp63gamma in epithelial to mesenchymal transition. J Biol Chem 2011;286:3915-24.
109. Oh JE, Kim RH, Shin KH, et al. DeltaNp63alpha protein triggers epithelial-mesenchymal transition and confers stem cell properties in normal human keratinocytes. J Biol Chem 2011;286: 38757-67.
110. Cowan CG, Gregg TA, Napier SS, et al. Potentially malignant oral lesions in northern Ireland: a 20-year population-based perspective of malignant transformation. Oral Dis 2001;7: 18-24.
111. Lodi G, Porter S. Management of potentially malignant disorders: evidence and critique. J Oral Pathol Med 2008;37:63-9.
112. Warnakulasuriya S. Squamous cell carcinoma and precursor lesions: prevention. Periodontol 2000 2011;57:38-50.
113. Silverman S, Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984;53: 563-8.
114. van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncol 2010;46: 423-5.
115. Lotan R. Retinoids and their receptors in modulation of differentiation, development, and prevention of head and neck cancers. Anticancer Res 1996;16:2415-19.
116. Lotan R, Xu XC, Lippman SM, et al. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. New Engl J Med 1995;332:1405-10.
117. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. New Engl J Med 1986;315:1501-5.
118. Papadimitrakopoulou VA, Hong WK, Lee JS, et al. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term followup. J Natl Cancer Inst 1997;89:257-8.
119. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998;90: 1545-51.
120. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. New Engl J Med 1993;328:15-20.
121. Papadimitrakopoulou VA, Lee JJ, William WN, Jr, et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 2009;27:599-604.
122. Stich HF, Hornby AP, Mathew B, et al. Response of oral leukoplakias to the administration of vitamin A. Cancer Lett 1988;40:93-101.
123. Stich HF, Rosin MP, Hornby AP, et al. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with betacarotene and with beta-carotene plus vitamin A. Int J Cancer 1988;42:195-9.
124. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol 1997;33:231-6.
125. Armstrong WB, Kennedy AR, Wan XS, et al. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 2000; 9:43-7.
126. Armstrong WB, Kennedy AR, Wan XS, et al. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000;6:4684-91.
127. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) 2009;2: 931-41.
128. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21:2895-900.
129. Henning SM, Niu Y, Lee NH, et al. Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplement. Am J Clin Nutr 2004;80: 1558-64.
130. Ahmad N, Cheng P, Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochemi Biophys Res Commun 2000;275:328-34.
131. Hastak K, Agarwal MK, Mukhtar H, et al. Ablation of either p21 or Bax prevents p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005; 19:789-91.
132. Kerr AR, Warnakulasuriya S, Mighell AJ, et al. A systematic review of medical interventions for oral submucous fibrosis and future research opportunities. Oral Dis 2011;17(Suppl 1):42-57.
133. Lippman SM, Gibson N, Subbaramaiah K, et al. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res 2005;11:6097-9.
134. Zhang X, Chen ZG, Choe MS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 2005;11:6261-9.
135. Li N, Sood S, Wang S, et al. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib. Clin Cancer Res 2005;11:2089-96.
136. Nishimura N, Urade M, Hashitani S, et al. Increased expression of cyclooxygenase (COX)22 in DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med 2004;33:614-21.
137. Mulshine JL, Atkinson JC, Greer RO, et al. Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia. Clin Cancer Res 2004;10: 1565-73.
138. Papadimitrakopoulou VA, William WN, Jr, Dannenberg AJ, et al. Pilot randomized phase II study of celecoxib in oral premalignant lesions. Clin Cancer Res 2008;14:2095-101.
139. Saba N, Muller S, Chen AY, et al. Chemoprevention with erlotinib and celecoxib in advanced premalignant lesions of the head and neck: results of a phase 1 study ASCO Annu Meet Proc 2010;28:5535.
140. Nankivell P, Dunn J, Langman M, et al. Feasibility of recruitment to an oral dysplasia trial in the United Kingdom. Head Neck Oncol 2012;4: 40.
141. Burns JE, Clark LJ, Yeudall WA, et al. The p53 status of cultured human premalignant oral keratinocytes. Br J Cancer 1994;70: 591-5.
142. Loughran O, Edington KG, Berry IJ, et al. Loss of heterozygosity of chromosome 9p21 is associated with the immortal phenotype of neoplastic human head and neck keratinocytes. Cancer Res 1994;54:5045-9.
143. McGregor F, Muntoni A, Fleming J, et al. Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine. Cancer Res 2002;62:4757-66.
144. McGregor F, Wagner E, Felix D, et al. Inappropriate retinoic acid receptor-beta expression in oral dysplasias: correlation with acquisition of the immortal phenotype. Cancer Res 1997;57: 3886-9.
145. Park NH, Min BM, Li SL, et al. Immortalization of normal human oral keratinocytes with type 16 human papillomavirus. Carcinogenesis 1991; 12:1627-31.
146. Sacks PG. Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck. Cancer Metastasis Rev 1996;15:27-51.
147. Liu X, Ory V, Chapman S, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012;180:599-607.
148. Guttenplan JB, Kosinska W, Zhao ZL, et al. Mutagenesis and carcinogenesis induced by dibenzo[a,l]pyrene in the mouse oral cavity: a potential new model for oral cancer. Int J Cancer 2012;130:2783-90.
149. Guttenplan JB, Spratt TE, Khmelnitsky M, et al. Effects of 3H-1,2-dithiole-3-thione, 1,4-phenylenebis(methylene)selenocyanate, and seleniumenriched yeast individually and in combination on benzo[a]pyrene-induced mutagenesis in oral tissue and esophagus in lacZ mice. Mutat Res 2004;559:199-210.
150. Kanojia D, Vaidya MM. 4-Nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol 2006;42:655-67.
151. Vitale-Cross L, Czerninski R, Amornphimoltham P, et al. Chemical carcinogenesis models for evaluating molecular-targeted prevention and treatment of oral cancer. Cancer Prev Res (Phila) 2009;2:419-22.
152. Ikenaga M, Ishii Y, Tada M, et al. Excisionrepair of 4-nitroquinolin-1-oxide damage responsible for killing, mutation, and cancer. Basic Life Sci 1975;5B:763-71.
153. Kim MM, Glazer CA, Mambo E, et al. Head and neck cancer cell lines exhibit differential mitochondrial repair deficiency in response to 4NQO. Oral Oncol 2006;42:201-7.
154. Hasina R, Martin LE, Kasza K, et al. ABT-510 is an effective chemopreventive agent in the mouse 4-nitroquinoline 1-oxide model of oral carcinogenesis. Cancer Prev Res (Phila) 2009;2:385-93.
155. Ide F, Kitada M, Sakashita H, et al. p53 haploinsufficiency profoundly accelerates the onset of tongue tumors in mice lacking the xeroderma pigmentosum group A gene. Am J Pathol 2003; 163:1729-33.
156. Ishikawa T, Ide F, Qin X, et al. Importance of DNA repair in carcinogenesis: evidence from transgenic and gene targeting studies. Mutat Res 2001;477:41-9.
157. Ma G, Sano K, Ikeda H, et al. Promotional effects of CO(2) laser and scalpel incision on 4-NQO-induced premalignant lesions of mouse tongue. Lasers Surg Med 1999;25:207-12.
158. von Pressentin MM, El-Bayoumy K, Guttenplan JB. Mutagenic activity of 4-nitroquinoline-Noxide in upper aerodigestive tissue in lacZ mice (MutaMouse) and the effects of 1, 4-phenylenebis(methylene)selenocyanate. Mutat Res 2000; 466:71-8.
159. von Pressentin MM, Kosinska W, Guttenplan JB. Mutagenesis induced by oral carcinogens in lacZ mouse (MutaMouse) tongue and other oral tissues. Carcinogenesis 1999;20:2167-70.
160. Czerninski R, Amornphimoltham P, Patel V, et al. Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model. Cancer Prev Res (Phila) 2009;2:27-36.
161. Vered M, Yarom N, Dayan D. 4NQO oral carcinogenesis: animal models, molecular markers and future expectations. Oral Oncol 2005;41:337-9.
162. Sumeth Perera MW, Gunasinghe D, Perera PA, et al. Development of an in vivo mouse model to study oral submucous fibrosis. J Oral Pathol Med 2007;36:273-80.
163. Wang Z, Polavaram R, Shapshay SM. Topical inhibition of oral carcinoma cell with polymer delivered celecoxib. Cancer Lett 2003;198:53-8.
164. Leeman-Neill RJ, Seethala RR, Singh SV, et al. Inhibition of EGFR-STAT3 signaling with erlotinib prevents carcinogenesis in a chemicallyinduced mouse model of oral squamous cell carcinoma. Cancer Prev Res (Phila) 2011;4:230-7.